Supplements No Help for Down Syndrome

Biogen's Phase 2/3 study showed a higher dose of nusinersen improves motor function in SMA infants, with plans for regulatory submission to advance treatment.

Findings from a newly-published study revealed that newborn metabolic profiles may identify infants at an increased risk for SIDS shortly after birth.

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to talk PGHD and the role of the pediatrician when it comes to treatment.

Can you diagnose this adolescent with an 11-day history of diffuse targetoid and bullous lesions on his extremities and trunk?